NIH-supported trials to test synthetic antibody treatments
Researchers have launched two clinical trials to test whether monoclonal (laboratory-made) antibodies can safely prevent SARS-CoV-2 infection or symptoms in healthy adults, the National Institutes of Health announced yesterday.
One trial will evaluate a Regeneron Pharmaceuticals investigational treatment in about 2,000 asymptomatic adults who are household contacts of people infected with SARS-CoV-2.
The other will assess an Eli Lilly and Company investigational treatment in up to 2,400 people who reside or work in skilled nursing or assisted living facilities.
Related News Articles
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…